郑慧;金金;蔡军;谢斌;

• 1:上海交通大学医学院附属精神卫生中心

摘要(Abstract)：

目的系统总结棕榈酸帕利哌酮(PP1M)治疗精神分裂症的药物经济学相关研究结果,为抗精神病药的临床应用提供依据。方法系统检索Taylor&Francis、ScienceDirect、PubMed、Embase、CBM、中国知网和万方数据库等,检索时间从建库至2019年12月,纳入2015～2019年棕榈酸帕利哌酮(PP1M)药物经济学相关的文献,并参照综合卫生经济学评价报告准则(CHEERS)量表评估文献质量。结果共纳入14篇对照研究,主要评价内容包括棕榈酸帕利哌酮(PP1M)相比其他抗精神病药在疗效、成本节约和质量调整生命年(QALYs)等方面的差异。多数研究结果支持棕榈酸帕利哌酮(PP1M)更具优效性,且通过敏感性分析验证了结果的稳定性。结论当前抗精神病药物中,棕榈酸帕利哌酮(PP1M)在治疗精神分裂症方面具有良好的药物经济学优势,同时棕榈酸帕利哌酮(PP3M)的成本效果优势较为明显。

关键词(KeyWords)： 棕榈酸帕利哌酮;精神分裂症;抗精神病药;药物经济学

Abstract:

Keywords:

基金项目(Foundation): 上海市卫生计生系统重要薄弱学科建设计划(2015-ZB0405);; 上海市“科技创新行动计划”临床医学领域项目(19411950801);; 上海市公共卫生体系建设三年行动计划(2020-2022年)重点学科建设计划项目(GWV-10.1-XK18)

作者(Author): 郑慧;金金;蔡军;谢斌;

Email:

DOI: 10.14053/j.cnki.ppcr.202103017

参考文献(References)：

• [1] Owen MJ,Sawa A,Mortensen PB.Schizophrenia[J].Lancet,2016,388(10039):86-97.
• [2] Jin H,Mosweu I.The societal cost of schizophrenia:a systematic review[J].Pharmacoeconomics,2017,35(1):25-42.
• [3] Charlson FJ,Ferrari AJ,Santomauro DF,et al.Global epidemiology and burden of schizophrenia:findings from the global burden of disease study 2016[J].Schizophr Bull,2018,44(6):1195-1203.
• [4] 国家卫生健康委办公厅.卫生健康工作状态[J].严重精神障碍信息管理工作专刊，2020.
• [5] Wang D,Gopal S,Baker S,et al.Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse[J].NPJ Schizophr,2018,4(1):10.
• [6] Fervaha G,Takeuchi H,Lee J,et al.Antipsychotics and amotivation[J].Neuropsychopharmacology,2015,40(6):1539-1548.
• [7] El Khoury AC,Pilon D,Morrison L,et al.The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia[J].Curr Med Res Opin,2019,35(3):395-405.
• [8] Husereau D,Drummond M,Petrou S,et al.Consolidated Health Economic Evaluation Reporting Standards(CHEERS)statement[J].Int J Technol Assess Health Care,2013,29(2):117-122.
• [9] Nuhoho S,Saad A,Saumell G,et al.Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates[J].Curr Med Res Opin,2018,34(4):601-611.
• [10] Druais S,Doutriaux A,Cognet M,et al.Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France[J].Pharmacoeconomics,2016,34(4):363-391.
• [11] Gozlan G,Lecardeur L,Monfort AS,et al.Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France[J].Encephale,2018,44(6):496-503.
• [12] Arteaga Duarte CH,Fakra E,Van Gils C,et al.The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France:a cost-utility study[J].Encephale,2019,45(6):459-467.
• [13] Einarson TR,Pudas H,Goswami P,et al.Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland[J].J Med Econ,2016,19(2):111-120.
• [14] Einarson TR,Bereza BG,Tedouri F,et al.Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands[J].J Med Econ,2017,20(11):1187-1199.
• [15] Muser E,Kozma CM,Benson CJ,et al.Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement[J].J Med Econ,2015,18(8):637-645.
• [16] Rosenheck RA,Leslie DL,Sint KJ,et al.Cost-effectiveness of long-acting injectable paliperidone palmitate versus haloperidol decanoate in maintenance treatment of schizophrenia[J].Psychiatr Serv,2016,67(10):1124-1130.
• [17] Einarson TR,Maia-Lopes S,Goswami P,et al.Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal[J].J Med Economics,2016,19(9):913-921.
• [18] Quintero J,Oyagüez I,González B,et al.Cost-minimisation analysis of paliperidone palmitate long-acting treatment versus risperidone long-acting treatment for schizophrenia in Spain[J].Clin Drug Investig,2016,36(6):479-490.
• [19] Einarson TR,Bereza BG,Garcia Llinares I,et al.Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain[J].J Med Econ,2017,20(10):1039-1047.
• [20] Roberto R,Giuseppe N,Marco V,et al.Cost-effectiveness analysis of paliperidone palmitate versus long-acting risperidone as maintenance treatment in schizophrenia patients in Italy[J].Global Regional Health Technol Assessment,2015,2(1):17-32.
• [21] 何汝帮，刘宜森，蔡小连.精神分裂症稳定期两种治疗方案的成本-效果比较[J].中国药物经济学，2015,10(2):8-10.
• [22] 何兆宇，吴胜，鲁陆，等.棕榈酸帕利哌酮注射液与帕利哌酮缓释片治疗精神分裂症的对比研究及经济学评价[J].中国医院用药评价与分析，2017,17(6):792-795.
• [23] Owen RT.Paliperidone palmitate injection:its efficacy,safety and tolerability in schizophrenia[J].Drugs Today(Barc),2010,46(7):463-471.
• [24] 张鸿燕，黄继忠，司天梅，等.棕榈酸帕利哌酮临床使用指导意见[J].中国新药杂志，2014,23(12):1410-1417.
• [25] National Institute of Mental Health.Schizophrenia.Bethesda,MD,USA[EB/OL].[2017-06-01].https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml.
• [26] Vos T,Allen C,Arora M,et al.Global,regional,and national incidence,prevalence and years lived with disability for 310 diseases and injuries,1990-2015:a systematic analysis for the global burden of disease study 2015[J].Lancet,2016,388(10053):1545-1602.
• [27] Chong HY,Teoh SL,Wu DB,et al.Global economic burden of schizophrenia:a systematic review[J].Neuropsychiatr Dis Treat,2016,12:357-373.
• [28] 周义湘，张苏菡，崔志强，等.棕榈酸帕利哌酮药物经济学系统评价[J].中国现代医生，2018,56(31):95-99,103.